Physician profile
Gerald Wallace
NPI 1972024974
$3,678.38
in general payments reported to CMS, 2019-2025
30 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $169 · 2021: $464 · 2022: $605 · 2023: $843 · 2024: $816 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,681.01 | 2021-2025 | Optune, Optune Gio |
| Alexion Pharmaceuticals, INC. | $340.56 | 2021-2025 | Koselugo, Ultomiris |
| Abbott Laboratories | $307.20 | 2022-2025 | Proclaim, Eterna |
| Greenwich Biosciences, INC. | $137.12 | 2019-2021 | |
| Seagen INC. | $125.00 | 2022 | |
| Neurelis, INC. | $108.80 | 2024 | Valtoco |
| Zap Surgical Systems, INC. | $99.93 | 2025 | Zap-X Treatment Planning Software, Zap-X Mv Imager, Zap-X Radiosurgery System |
| Novocure Gmbh | $98.68 | 2023 | Optune |
| Depuy Synthes Sales INC. | $71.21 | 2019-2020 | |
| Amgen INC. | $66.38 | 2020-2024 | |
| Biogen, INC. | $58.38 | 2019-2025 | Spinraza |
| Foundation Medicine, INC. | $57.27 | 2022 | |
| Sk Life Science, INC. | $53.11 | 2022-2023 | |
| Pfizer INC. | $51.68 | 2019 | |
| Abbvie INC. | $46.61 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $37.07 | 2024 | Carvykti, Tecvayli, Talvey |
| Livanova USA, INC. | $36.03 | 2020-2021 | |
| Argenx US, INC. | $29.02 | 2024 | Vyvgart Hytrulo |
| Eisai INC. | $29.02 | 2019 | |
| Averitas Pharma INC. | $28.69 | 2025 | Qutenza |
| Allergan, INC. | $28.28 | 2020-2021 | |
| Tg Therapeutics, INC. | $26.30 | 2025 | |
| Tanabe Pharma America, INC. | $24.76 | 2024 | |
| Azurity Pharmaceuticals, INC. | $24.72 | 2024 | Zonisade |
| Takeda Pharmaceuticals U.S.A., INC. | $23.40 | 2023 | Gammagard |
| Ucb, INC. | $20.83 | 2025 | Rystiggo |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Neurocrine Biosciences, INC. | $17.88 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2023 | Austedo |
| Genzyme Corporation | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.